BMS files first drug from triple bet with Celgene shareholde...

Bristol-Myers Squibb has filed the first of three key drugs with the FDA, part of a triple “bet” with former investors in Celgene that could pay out billions if they all successfully make i

BMS preps filings for leukaemia maintenance therapy CC-486

Brisk trade in risky three-drug 'bet' option after BMS/Celge...

Bristol-Myers Squibb’s $74 billion merger with Celgene went ahead this week after clearance from US competition regulators, and the focus has shifted on to whether Celgene shareholders will

$74bn BMS/Celgene merger finally cleared by competition regu...

Bristol-Myers Squibb and Celgene’s merger looks set to close tomorrow after US competition regulators finally gave the $74 billion deal the go-ahead.

Celgene scores FDA okay for thalassaemia drug Reblozyl

The top pharma companies by revenue 2018